1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Netherton Syndrome Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapy, and Geography

Netherton Syndrome Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapy, and Geography

  • September 2020
  • 76 pages
  • ID: 5978096
  • Format: PDF
  • The Insight Partners
Up to $1700 off Until Nov 30th 2020

Summary

Table of Contents

Search Inside

The Netherton syndrome market was valued at US$ 19.57 million in 2019 and is projected to reach US$ 74.31 million by 2027; it is expected to grow at a CAGR of 20.3%during 2020–2027.

The growth of the Netherton syndrome market is mainly attributed to factors such as the rising number of awareness campaigns, and increasing number of drug launches and robust product pipeline. However, side-effects of Netherton syndrome drugs limit the growth of the market.

Various companies around the world are focused on launching and developing new, effective, and innovative therapies for rare diseases, including Netherton syndrome. It is a chronic genetic skin disease that can turn life threatening; people suffering with the Netherton syndrome face immunity-related issues such as food allergies, hay fever, asthma, and eczema, i.e., an inflammatory skin disorder.

In May 2020, Azitra, Inc., a clinical-stage medical dermatology drug manufacturer, received Rare Pediatric Disease Designation to ATR-12 from the US Food and Drug Administration (FDA) for the treatment of Netherton syndrome (NS). Moreover, in April 2010, LifeMax Laboratories, Inc. received fast track designation for its LM-030, an investigational therapy licensed from Novartis and currently in a Phase 2/3 pivotal clinical trial for the treatment of Netherton Syndrome, by the FDA. Moreover, in July 2020, SixeraPharma developed a treatment for Netherton syndrome that targets and specifically certain proteases in the skin.

Further, a large number of investors are financing projects focused on rare diseases. For instance, in May 2020, Toronto Innovation Acceleration Partners (TIAP), Evotec SE, and AmorChem II Fund L.P. invested US$ 1.75 million into a drug development project focused on Netherton Syndrome, a rare skin disease that affects one in 200,000 newborns worldwide. Thus, the increasing emphasis on developing rare disease treatment options and a promising pipeline for the development of drug candidates to treat Netherton syndrome encourage the growth of the market.

Based on therapy, the global Netherton syndrome market is segmented into keratolytic agents, oral and topical steroids and retinoid, topical calcineurin inhibitors, biological therapy, and radiation therapy.In 2019, the keratolytic agents segment held the largest share of the global Netherton syndrome market.

Growth of this segment is attributed to the increasing drug launches and robust pipeline.In addition, strategic activities by service providers such as collaborations, merger acquisition and expansion in order to expedite drug timeline are further accelerating the growth of the market.

In addition, implementation of government programs regarding awareness of the Netherton syndrome are also likely to have positive impact on the growth of the market during the forecast period. However, biological therapy segment in the global Netherton syndrome market is estimated to register considerable growth during the forecast period.

The World Health Organization (WHO), Food and Drug Administration (FDA), National Health Service (NHS), and Centers for Disease Control and Prevention (CDC) are a few of the major primary and secondary sources referred for preparing this report.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($4500)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Ulcerative Colitis - Epidemiology Forecast to 2029

  • $ 3995
  • October 2020
  • 58 pages

Ulcerative Colitis - Epidemiology Forecast to 2029 Summary Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the large intestine and the rectum.The ...

  • United Kingdom
  • Canada
  • Autoimmune Disease
  • Epidemiology
  • Industry analysis
  • Hospital Admission
  • Prescription Drug Sales

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on